Letrozole Accord

Letrozole, the active ingredient in Letrozole Accord, is an aromatase inhibitor presented as a tablet for oral use. It is employed to treat hormone receptor‑positive breast cancer in postmenopausal women. GNH USA supplies Letrozole Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozole is an aromatase inhibitor used in the management of hormone‑dependent breast cancer.

Hormone receptor‑positive breast cancer (postmenopausal): reduces estrogen production to limit tumor growth. Advanced or metastatic breast cancer (postmenopausal): helps control disease progression. Adjuvant therapy after surgery (postmenopausal): decreases risk of cancer recurrence.

Adverse reactions may occur with Letrozole therapy.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: aching in joints or muscles. - Fatigue: persistent tiredness. - Nausea: mild stomach upset. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated liver enzymes. - Bone fracture: increased risk due to reduced bone density. - Pulmonary embolism: sudden shortness of breath or chest pain. - Allergic reactions: rash, swelling, or anaphylaxis. - Severe hypertension: markedly high blood pressure.

Before initiating Letrozole, several safety considerations are recommended.

Pregnancy: contraindicated (Category X); avoid use in pregnant women. Bone health: monitor bone mineral density regularly. Cardiovascular risk: assess and manage underlying heart disease. Liver function: evaluate hepatic status prior to treatment. Drug interactions: review concomitant medications for potential effects. Store at room temperature: keep in the original container, protect from moisture and light.

Letrozole may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may lower letrozole levels. - Tamoxifen: antagonistic effect on estrogen suppression. - Estrogen replacement therapy: counteracts letrozole action.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR and bleeding risk. - CYP2C19 inhibitors (e.g., fluconazole): may raise letrozole plasma concentrations. - Statins: monitor for potential muscle toxicity.